[Dynamics of immunological and clinical parameters in the treatment of childhood schizophrenia].
A state of innate and adaptive immunity (leukocyte elastase (LE) activity, alpha(1)-proteinase inhibitor (alpha(1)-PI), the level of autoantibodies to nerve growth factor (Aab-NGF) and to basic myelin protein), have been studied in the blood serum of children with schizophrenia and compared to the changes of their clinical-psychopathological state. It has been shown that the exacerbation of schizophrenic process with early onset is accompanied by the activation of some parameters of innate immunity. But the higher activity of LE and alpha(1)-PI before the treatment cannot be considered as a predictive marker of therapeutic efficacy. At the same time, the decrease of LE activity during the treatment is a significant predictor of favorable therapeutic response. The unchanged level of Aab-NGF comparing to controls is also a favorable factor associated with therapeutic efficacy.
Kliushnik
T P
TP
Kalinina
M A
MA
Sarmanova
Z V
ZV
Otman
I N
IN
Kozlovskaia
G V
GV
D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D007124:Immunoenzyme Techniques; D019272:Leukocyte Elastase / Q000097:blood*; D008297:Male; D020932:Nerve Growth Factor / Q000097:blood* / Q000276:immunology; D011379:Prognosis; D011479:Protamines / Q000097:blood* / Q000276:immunology; D012189:Retrospective Studies; D012559:Schizophrenia / Q000097:blood / Q000276:immunology* / Q000628:therapy; D012720:Severity of Illness Index; D000515:alpha 1-Antitrypsin / Q000097:blood*
D014150:Antipsychotic Agents; D001323:Autoantibodies; D015415:Biomarkers; D011479:Protamines; D000515:alpha 1-Antitrypsin; C068621:protamine 2; D020932:Nerve Growth Factor; D019272:Leukocyte Elastase